Nasdaq
$3.62▲ 0.70%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $163.4MShares out 45.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 9.21After-hours26.09.22 07:57SCHEDULE 13D/AOwnership#●●●#●●●
Sionna Therapeutics, Inc.
RA Capital Management, L.P. has filed a Schedule 13D/A regarding its beneficial ownership in Sionna Therapeutics, Inc. This filing serves to update the status of the investor's holdings in the company.…more
$3.62+0.70%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.21After-hours26.09.22 07:564Ownership
Sionna Therapeutics, Inc.
A Form 4 filing has been submitted disclosing that RA Capital Management and its affiliated funds hold a significant stake in Sionna Therapeutics, Inc. The reporting entities have formalized their ownership and changes in equity as of September 17, 2026.…more
$3.62+0.70%vs prev closeView filingShare - 9.18After-hours26.09.19 05:594Ownership
Sionna Therapeutics, Inc.
Insider Elena Ridloff of Sionna Therapeutics filed a Form 4 report regarding changes in beneficial ownership of securities as of September 17, 2026. This filing serves as an official disclosure of executive equity transactions.…more
$3.62+0.70%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.8After-hours26.10.09 05:30#●●●#●●●
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference…more
Sionna Therapeutics presented clinical and preclinical data for its cystic fibrosis candidates at the 2026 North American Cystic Fibrosis Conference. The company plans to initiate a new Phase 2a proof-of-concept trial in the first quarter of 2027 based on these findings.…more
$3.62+0.70%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.14After-hours26.09.15 05:01
●●●●●●●● ●●●●● ●●●●●●
Sionna Therapeutics plans to advance a new drug combination into Phase 2a trials following a post hoc analysis of previous results, while cutting its workforce by 46% to extend its cash runway. The restructuring highlights financial pressure, leading to a neutral outlook.…more
$3.62+0.70%vs prev close - 8.10Pre-market26.08.10 20:00
●●●●●●●● ●●●●● ●●●●●●
시오나 테라퓨틱스가 낭성섬유증 치료제 개발 프로그램의 주요 임상 데이터를 공개하며 기업 현황을 업데이트했습니다. 향후 치료제 개발 성과에 따른 시장의 반응과 기업 가치 변화를 주시할 필요가 있습니다.…more
$3.62+0.70%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report